 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| «12...1516171819202122232425...134135» |
- | Journal: Hesperetin ameliorates spinal cord injury by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. (Pubmed Central) - Apr 25, 2023
Furthermore, the silencing of Nrf2 by small interfering ribonucleic acid (siRNA) partially abolished its antioxidant effect in the aforementioned cell experiments. Collectively, these findings illustrate that through an increase in Nrf2 signaling hesperetin reduces oxidative stress and neuroinflammation by suppressing NLRP3 inflammasome activation and pyroptosis.
- | Journal: Leukadherin-1 inhibits NLRP3 inflammasome by blocking inflammasome assembly. (Pubmed Central) - Apr 25, 2023
Instead, it inhibited NLRP3 inflammasome assembly by suppressing ASC oligomerization, blocking NLRP3 self-assembly, and reducing interactions of NLRP3 with ASC and NEK7. Therefore, LA-1 inhibits NLRP3 inflammasome activation, implying that it is a potential treatment option for NLRP3-associated diseases.
- | Journal: Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer. (Pubmed Central) - Apr 14, 2023
Moreover, metabolic stability in liver microsomes of 6c, 7n, and 10 was studied along with plasma exposure in mice of the most interesting compound 6c. Therefore, we generated potent NLRP3 inflammasome inhibitors, which can be considered in future medicinal chemistry and pharmacological studies aimed at developing a new therapeutic approach for NLRP3 inflammasome-driven cancer.
- | Journal: Novel Activity of ODZ10117, a STAT3 Inhibitor, for Regulation of NLRP3 Inflammasome Activation. (Pubmed Central) - Apr 13, 2023
release and the mortality rate of mice with LPS-induced sepsis. Collectively, these results demonstrate a novel effect of ODZ10117 in regulating NLRP3 inflammasome activation both in vitro and in vivo, making it a promising candidate for the treatment of NLRP3-inflammasome-associated immune disorders and cancer.
- | Journal: Narirutin exerts anti-inflammatory activity by inhibiting NLRP3 inflammasome activation in macrophages. (Pubmed Central) - Apr 13, 2023
Furthermore, oral administration of narirutin (300?mg/kg) alleviated inflammation symptoms in mice with peritonitis and colitis. These results suggest that narirutin exerts its anti-inflammatory activity by suppressing NLRP3 inflammasome activation via inhibition of the NLRP3 inflammasome priming processes and NLRP3-ASC interaction in macrophages.
- MCC950 reduces glial cell activation and neuroinflammation in an animal model of thioacetamide-induced hepatic encephalopathy (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_986;
The findings from the current study for the first time demonstrated that treatment with MCC950 a direct inhibitor of NLRP3 inflammasome reduced hepatic injury, neuroinflammation, increased integrity of tight junction proteins and survival rate in HE rats. Altogether, these findings suggest that inhibition of NLRP3 inflammasome may be considered as a novel potential target for HE in the future.
- Edurant (rilpivirine) / J&J
Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_660;
The antiretroviral drug RPV exerts anti-inflammatory actions on injured hepatocytes, activated HSC, macrophages and PBMC. The findings point to a beneficial role of RPV in NAFLD.
- Inhibition of NLRP3 inflammasome activation by MK571, an multidrug resistance-associated protein (MRP) inhibitor (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_605;
The findings point to a beneficial role of RPV in NAFLD. These findings indicate that the MRP4 and 5 as energy-dependent transporters for the cyclic nucleotide, are involved in the regulation of NLRP3 inflammasome during liver injury.
- | Journal: Holomycin, a novel NLRP3 inhibitor, attenuates cartilage degeneration and inflammation in osteoarthritis. (Pubmed Central) - Apr 12, 2023
In DMM mouse models, intra-articular administration of HL alleviated cartilage degeneration and inflammation, as evidenced by the decrease of OARSI score and MMP13, p16, p21, Collagen II, IL-6, and CXCL-1 expressions and the restoration of chondrocyte number, proteoglycan, and MMP13 expression in cartilage tissues. This study identified HL as a promising agent for OA.
- | paracetamol / Generic mfg.
Journal: Oridonin ameliorates acetaminophen-induced acute liver injury through ATF4/PGC-1? pathway. (Pubmed Central) - Apr 12, 2023
Our findings demonstrated that Ori prevented metabolic activation of APAP and further inhibited the ATF4/PGC-1? pathway to alleviate APAP overdose-induced hepatic toxicity, which illuminated its potential therapeutic effects on ALI.
- Lyososome Membrane Permeabilization Induces Plasma Membrane Macropores to Activate K+-Efflux-Dependent NLRP3 Inflammasomes in Murine Dendritic Cells (P660) (Exhibit Hall; Poster Board No. P660) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1976;
These observations indicate that LMP triggers rapid activation of an endogenous pore-forming protein distinct from GSDMD. Current studies are evaluating gasdermin E or pannexin-1 as candidates.
- Discovery of a novel orally bioavailable NLRP3 inflammasome inhibitor, TTS-X, for potential treatment of inflammatory bowel disease (P807) (Exhibit Hall; Poster Board No. P807) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1294;
Collectively, these results suggest that TTS-X is a potent and oral bioavailable NLRP3 inhibitor with biological activity in vivo. Further characterization of this lead compound is under way for potential treatment of inflammatory bowel disease and other NLRP3-driven diseases
- Galectin-3 contributes to pathogenesis of IgA nephropathy (P837) (Exhibit Hall; Poster Board No. P837) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_740;
These results suggest that Gal-3 is critically involved in IgAN pathogenesis by activating the NLRP3 inflammasome and promoting Th17 cell differentiation. Therefore, targeting Gal-3 action may represent a new therapeutic strategy for treatment of this renal disease.
- CARD-only proteins (COPs) inhibit uric acid crystal-induced inflammasome activation and ameliorate gout. (P832) (Exhibit Hall; Poster Board No. P832) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_603;
We demonstrate that COPs are functional in mice and inhibit NLRP3 inflammasome assembly by a competitive binding mechanism that prevents cytokine release and pyroptotis and ameliorates inflammatory disease. Altogether, our findings illustrate that the COPs have a role in maintaining homeostasis.
- Bi-directional epithelial-immune communication amplifies inflammasome activation and IL-6 release during SARS-CoV-2 infection (P827) (Exhibit Hall; Poster Board No. P827) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_597;
This circuit is reflected in patient data, as COVID-19 autopsy lungs show hallmarks of inflammasome priming and activation in myeloid populations lacking SARS-CoV-2 antigens. Meta-analysis of single cell RNA sequencing (scRNAseq) data reveals discordant, exacerbated priming of inflammasomes in myeloid cells from severe but not mild COVID-19 patients, indicating this circuit is intensified in severe disease.
- Neutrophil Inflammasome Is Activated in Diabetes and Contributes to the Exacerbated NETosis (Poster Halls B-C; [Board No. 1482]) - Apr 10, 2023 - Abstract #ADA2023ADA_836;
In summary, our findings suggest that mitochondria and ER stress may synergize in the activation of neutrophil NLRP3 that exacerbates NETosis in diabetes. Therapeutics that aim at intercepting the pathway may alleviate NET-mediated chronic inflammation in diabetes.
- | Preclinical, Journal: Protective effect of quercetin on pulmonary dysfunction in streptozotocin-induced diabetic rats via inhibition of NLRP3 signaling pathway. (Pubmed Central) - Apr 5, 2023
In conclusion, NLRP3 inflammasome-induced pyroptosis may aggravate lung injury in diabetic rats. Quercetin has the potential to ameliorate diabetes induced pulmonary dysfunction by targeting NLRP3.
- | Journal: Knockdown of PHLDA1 Alleviates Necrotizing Enterocolitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Through Enhancing Nrf2 Signaling. (Pubmed Central) - Apr 4, 2023
In addition, sh-PHLDA1 was able to inhibit NLRP3 activation and pyroptosis by activating Nrf2. Knockdown of PHLDA1 attenuated necrotizing small intestinal colitis by enhancing Nrf2 expression to inhibit NLRP3 inflammasome activation and pyroptosis.
- | Journal: The involvement of DDX3X in compression-induced nucleus pulposus pyroptosis. (Pubmed Central) - Apr 3, 2023
Our study showed that DDX3X mediates pyroptosis of NP cells by upregulating NLRP3 expression, which ultimately leads to intervertebral disc degeneration (IDD). This discovery deepens the understanding of IDD pathogenesis and provides a promising and novel therapeutic target for IDD.
- | Preclinical, Journal: Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity. (Pubmed Central) - Apr 3, 2023
Collectively, we reported SHTB as a TCM targeting Prkaa1 for anti-inflammation to improve intestinal barrier in mice with constipation. These findings broaden our knowledge of Prkaa1 as a druggable target protein for inflammation inhibition, and open a new avenue to novel therapy strategy for constipation injury.
- Miostat (carbachol) / Novartis
Diabetes causes temporal changes in cholinergic-mediated bladder contractility due to inflammation via the NLRP3 inflammasome in female Akita mice (S401C) - Mar 30, 2023 - Abstract #AUA2023AUA_2476;
This suggests an NLRP3 inhibitor may be an effective therapy to prevent overactive bladder and eliminate the need for conventional anti-cholinergic treatments. SOURCE OF
- | Journal: Sulforaphene targets NLRP3 inflammasome to suppress M1 polarization of macrophages and inflammatory response in rheumatoid arthritis. (Pubmed Central) - Mar 30, 2023
As revealed by mouse experimental results, LF inhibited bone injury in mice, decreased M1 cell infiltration and inflammatory response in tissues, and inhibited NLRP3 inflammasome expression in tissues. LF targets NLRP3 to suppress the M1 polarization of macrophages and decrease tissue inflammation in RA.
- | Journal: Mitochondrial GRIM-19 loss in parietal cells promotes spasmolytic polypeptide-expressing metaplasia through NLR family pyrin domain-containing 3 (NLRP3)-mediated IL-33 activation via a reactive oxygen species (ROS) -NRF2- Heme oxygenase-1(HO-1)-NF-?B axis. (Pubmed Central) - Mar 30, 2023
Our study suggests that mitochondrial GRIM-19 maybe a potential pathogenetic target for the SPEM pathogenesis, and its deficiency promotes SPEM through NLRP3/IL-33 pathway via a ROS-NRF2-HO-1-NF-?B axis. This finding not only provides a causal link between GRIM-19 loss and SPEM pathogenesis, but offers potential therapeutic strategies for the early prevention of intestinal GC.
- | esomeprazole / Generic mfg.
Journal: NLRP3 inhibition improves maternal hypertension, inflammation, and vascular dysfunction in response to placental ischemia. (Pubmed Central) - Mar 30, 2023
NLRP3 inhibition, with either treatment, significantly reduced placental NLRP3 expression, maternal blood pressure, fetal reabsorption rates, vascular resistance, oxidative stress, cNK and T17 populations in RUPP rats. Based on our findings, NLRP3 inhibition reduces PE pathophysiology and esomeprazole may be a potential therapeutic for PE treatment.
- || RRx-001 / EpicentRx
Review, Journal: A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation. (Pubmed Central) - Mar 29, 2023
P3
Studies from multiple independent groups have now confirmed that RRx-001 is safe and well tolerated in humans. Additionally, emerging evidence in preclinical animal models suggests that RRx-001 could be effective in a wide range of diseases where immune and inflammasome activation drives disease pathology.
- || Review, Journal: Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). (Pubmed Central) - Mar 29, 2023
According to the retrieved literature, the current understanding of NLRP3 inflammasome pathway activation in inflammatory diseases was summarize, and inhibitors of the NLRP3 inflammasome pathway targeting the NLRP3 protein and other inflammasome components or products were highlighted. Additionally, the present review briefly discusses the current novel efforts in clinical research.
- || RRx-001 / EpicentRx, Opdivo (nivolumab) / Ono Pharma, BMS
P1 data, Clinical Trial,Phase I, Journal, Metastases: Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). (Pubmed Central) - Mar 29, 2023
P1
Further clinical trials with RRx-001 and nivolumab are warranted. ClinicalTrials.gov identifier, NCT02518958.
- || Review, Journal: The Potential of NLRP3 Inflammasome as a Therapeutic Target in Neurological Diseases. (Pubmed Central) - Mar 28, 2023
More importantly, despite small-molecule inhibitors of the NLRP3 inflammasome, we have focused explicitly on Chinese herbal medicine and botanical ingredients, which may be splendid therapeutics by inhibiting NLRP3 inflammasome for central nervous system disorders. We expect that we can contribute new perspectives to the treatment of neurological diseases.
- | fingolimod / Generic mfg.
Journal: Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure. (Pubmed Central) - Mar 28, 2023
We expect that we can contribute new perspectives to the treatment of neurological diseases. The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.
- | Journal: The aqueous extracts of Ageratum conyzoides inhibit inflammation by suppressing NLRP3 inflammasome activation. (Pubmed Central) - Mar 27, 2023
The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS. Our results demonstrated that EAC inhibited inflammation by suppressing NLRP3 inflammasome activation, highlighting that this traditional herbal medicine might be used to treat NLRP3 inflammasome-driven inflammatory diseases.
- | Journal: TNF?-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2. (Pubmed Central) - Mar 27, 2023
This study highlights the importance of adipocyte NLRP3 inflammasome activation and novel role of TNF?-NLRP3-Lcn2 axis in adipose tissue. It adds rational for the current development of NLRP3 inhibitors for treating obesity-induced metabolic diseases.
- | simvastatin / Generic mfg.
Journal: Polydatin protects against atherosclerosis by activating autophagy and inhibiting pyroptosis mediated by the NLRP3 inflammasome. (Pubmed Central) - Mar 27, 2023
It adds rational for the current development of NLRP3 inhibitors for treating obesity-induced metabolic diseases. Polydatin can inhibit the activation of the NLRP3 inflammasome and cleavage of caspase-1, thereby inhibiting pyroptosis and secretion of inflammatory cytokines, and promoting autophagy through NLRP3/mTOR pathway in AS.
- | Journal: Secondary White Matter Injury Mediated by Neuroinflammation After Intracerebral Hemorrhage and Promising Therapeutic Strategies of Targeting the NLRP3 Inflammasome. (Pubmed Central) - Mar 27, 2023
Therefore, NLRP3 inflammasome may act as leveraged regulatory fulcrums for microglia and astrocytes polarization to modulate WMI and WM repair after ICH. This review summarized the possible mechanisms by which neuroinflammation mediated by NLRP3 inflammasome exacerbates secondary WMI after ICH and discussed the potential therapeutic targets.
- | Preclinical, Journal: Sinoline inhibits NLRP3 and downstream inflammatory factors to alleviate the arthritis symptoms in adjuvant arthritis rats (Pubmed Central) - Mar 25, 2023
in serum in sinoline treatment groups. Conclusion Sinolin can improve joint inflammation in AA rats by inhibiting NLRP3 and downstream inflammatory factors.
- | Journal: Inflammasome inhibition protects dopaminergic neurons from ?-synuclein pathology in a model of progressive Parkinson's disease. (Pubmed Central) - Mar 25, 2023
MCC950-treated mice showed significantly less neurodegeneration of DA neurons and a reduction in PD-related motor behavior. In summary, early inflammasome inhibition can reduce neuroinflammation and prevent DA cell death in an ?-synuclein mouse model for progressive PD.
- 17b-estradiol Prevents NLRP3 Activation and Contractile Dysfunction in Right Ventricles and Right Ventricle Cardiomyocytes From Rats With Pulmonary Hypertension (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6945;
E2 prevents NLRP3 activation and NLRP3-induced RV dysfunction in an ER?-dependentmanner. E2-mediated NLRP3 inhibition may underly sexual dimorphisms in RV adaptation.
- | Preclinical, Journal: Protective effects of Bifidobacterium bifidum FL-228.1 on dextran sulfate sodium-induced intestinal damage in mice. (Pubmed Central) - Mar 24, 2023
E2-mediated NLRP3 inhibition may underly sexual dimorphisms in RV adaptation. Bifidobacterium bifidum FL-228.1 may be developed as a promising probiotic for the prevention of intestinal barrier damage via PPAR?/NLRP3/ TLR2 pathways by enhancing Muc2 and Cldn-4.
- | Journal: Puerarin protects against sepsis-associated encephalopathy by inhibiting NLRP3/Caspase-1/GSDMD pyroptosis pathway and reducing blood-brain barrier damage. (Pubmed Central) - Mar 24, 2023
Our findings suggest that puerarin may improve SAE by inhibiting the classical pathway of NLRP3/Caspase-1/GSDMD-mediated pyroptosis and reducing blood-brain barrier damage, thus playing a role in brain protection. Our study may provide a novel therapeutic strategy for SAE.
- | Journal: Coenzyme Q defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1? expression in human triple-negative breast cancer cells. (Pubmed Central) - Mar 24, 2023
The present study revealed that suppression of HIF-1? expression caused by CoQ may contribute to inhibition of NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects of triple-negative breast cancers.
- LIVER FIBROSIS IS EXACERBATED BY ALCOHOL BINGES IN MURINE NASH VIA NLRP3-DEPENDENT NEUTROPHIL EXTRACELLULAR TRAPS FORMATION WHICH MEDIATES ACTIVATION OF HEPATIC STELLATE CELLS (S404 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_2273;
NETs directly induce a pro-fibrotic stellate cell phenotype via NLRP3. Inhibition of NLRP3 attenuates NET formation and in vivo NLRP3 inhibition may represent a target to attenuate the pro-fibrotic effect of alcohol in NASH fibrosis.
- | acetylcysteine solution / Generic mfg., paracetamol / Generic mfg.
Journal: Mitochondrial-Targeted Delivery of Polyphenol-Mediated Antioxidases Complexes against Pyroptosis and Inflammatory Diseases. (Pubmed Central) - Mar 21, 2023
More interestingly, TSC maintained superior efficacy compared with the clinical gold standard drug N-acetylcysteine in both acetaminophen- and D-galactosamine/lipopolysaccharide-induced pyroptosis-related hepatitis mouse models. In conclusion, this study opens a new paradigm for targeting mitochondrial oxidative stress to inhibit pyroptosis and treat inflammatory diseases.
- | Preclinical, Journal: NLRP3 Plays a Key Role in Antihelminth Immunity in the Enteral and Parenteral Stages of Trichinella spiralis-Infected Mice. (Pubmed Central) - Mar 21, 2023
This study revealed that NLRP3 is involved in the host response to T. spiralis infection and that targeted inhibition of NLRP3 enhanced the Th2 response and accelerated T. spiralis expulsion. These findings may help in the development of protocols for controlling trichinellosis.
- | Zanosar (streptozocin) / Teva
Journal: Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway. (Pubmed Central) - Mar 21, 2023
Inhibition of Nrf2 reversed the protective effect of TP on MPC5 cells. Overall, TP alleviated podocyte injury in DN by inhibiting OS and pyroptosis via Nrf2/ROS/NLRP3 axis.
- | sevoflurane / Generic mfg.
Preclinical, Journal: Sevoflurane preconditioning improves neuroinflammation in cerebral ischemia/reperfusion induced rats through ROS-NLRP3 pathway. (Pubmed Central) - Mar 20, 2023
Overall, TP alleviated podocyte injury in DN by inhibiting OS and pyroptosis via Nrf2/ROS/NLRP3 axis. Sevoflurane could alleviate cerebral I/R-induced brain damage by inhibiting the ROS-NLRP3 pathway.
- | Journal: YAP1 protects against PM2.5-induced lung toxicity by suppressing pyroptosis and ferroptosis. (Pubmed Central) - Mar 20, 2023
In contrast, YAP1-overexpressing cells inhibited NLRP3 inflammasome activation and increased SLC7A11 levels, preventing pyroptosis and ferroptosis. Overall, our data suggest that YAP1 ameliorates PM2.5-induced lung injury by inhibiting NLRP3-mediated pyroptosis and SL7A11-dependent ferroptosis.
- | Preclinical, Journal: Discovery of pterostilbene analogs as novel NLRP3 inflammasome inhibitors for potential treatment of DSS-induced colitis in mice. (Pubmed Central) - Mar 20, 2023
Preliminary mechanism studies showed that compound D22 may affect the assembly of NLRP3 inflammasome by targeting NLRP3 protein, thereby inhibiting the activation of NLRP3 inflammasome. The in vivo anti-inflammatory activity indicated that compound D22 had significant therapeutic effects on DSS-induced mouse acute colitis models.
- | Journal: Human Cytomegalovirus infection activates NLRP3 inflammasome by releasing mtDNA into cytosol in human THP-1 cells. (Pubmed Central) - Mar 19, 2023
after HCMV infecion. In conclusion, HCMV infection of THP-1 cells resulted in decreased mitochondrial TFAM protein expression and increased mtDNA release into the cytoplasm, which eventually led to the activation of NLRP3 inflammasome.
- | hydroxychloroquine / Generic mfg.
Preclinical, Journal: Oral hydroxychloroquine mitigates lipopolysaccharide-induced lung injury by inhibiting pyroptosis in mice. (Pubmed Central) - Mar 16, 2023
In conclusion, HCMV infection of THP-1 cells resulted in decreased mitochondrial TFAM protein expression and increased mtDNA release into the cytoplasm, which eventually led to the activation of NLRP3 inflammasome. Taken together, HCQ protects against lung injury by inhibiting pyroptosis, maybe not only through the NLRP3 pathway but also through non-NLRP3 pathway; therefore, it may be a new therapeutic strategy in the treatment of lung injury.
- | Journal, IO biomarker: Tectorigenin inhibits inflammation in keratinocytes by inhibition of NLRP3 inflammasome regulated by the TLR4/NF-?B pathway. (Pubmed Central) - Mar 15, 2023
Taken together, HCQ protects against lung injury by inhibiting pyroptosis, maybe not only through the NLRP3 pathway but also through non-NLRP3 pathway; therefore, it may be a new therapeutic strategy in the treatment of lung injury. This study proves that tectorigenin may be a potential therapeutic candidate for psoriasis treatment in future.
- | Journal: Polyaspartic Acid-Stabilized CaCO-Containing In Situ Hydrogel for Protection and Treatment of Gastric Ulcer. (Pubmed Central) - Mar 15, 2023
Importantly, the protective barrier formed by the SA/PC hydrogel could effectively protect against alcohol-induced acute gastric ulcers in rats. Overall, the designed SA/PC oral delivery system is a promising strategy to overcome gastric barriers for oral drug delivery.